Background. Current phenotypic testing for drug resistance in patients with tuberculosis is inadequate primarily with respect to turnaround time. Molecular tests hold the promise of an improved time to diagnosis.
assay because patients with rifampin-resistant tuberculosis require treatment with second-line antituberculosis drugs [5] . A number of other molecular tests are now in the pipeline, with some aiming for an increased drug resistance testing portfolio [6] . Several novel molecular tests are being developed for the peripheral laboratory setting, as opposed to the centralized, referral laboratory [7] .
A tuberculosis test that provides results in <2 hours can enable a decision on which regimen to choose or a referral decision at the time of the patient's first visit to a tuberculosis treatment center (ie, at the point of care) [8, 9] . This is especially relevant over the coming years as novel alternative first regimens are emerging [10, 11] . Currently, there is only 1 firstline regimen, which includes isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE). An alternative regimen evaluated for first-line therapy, REMox (rifampin, moxifloxacin, pyrazinamide, and ethambutol or isoniazid), was recently shown to be inferior to HRZE in a phase 3 clinical study [12] , but other fluoroquinolone-based regimens are being explored [13] . Figure 1 shows the current tuberculosis drug pipeline. PaMZ (Pa824, moxifloxacin, and pyrazinamide) was shown to be effective in a phase 2b trial [14] and will be evaluated in a phase 3 trial, which started in November 2014. If the phase 3 study shows this regimen to be beneficial, it could be implemented over the coming years ( planned start, 2018) as an alternative to the standard regimen.
A detailed, consensus-based target product profile (TPP) is necessary to align new tuberculosis diagnostic test development with new tuberculosis drug regimens and outline the characteristics of resistance testing that would meet medical and public health needs at the level of the microscopy center, to inform test developers [15] .
METHODS
The development of the TPP described here was a collaborative effort that included opinions from researchers, clinicians, policy makers (global and national), and test developers. First, we mapped the current diagnostic ecosystem to understand which diagnostic tests are used in disease-endemic countries and Figure 1 . Tuberculosis Alliance pipeline. Reproduced with permission of the TB Alliance [13] . specific healthcare settings. This was based on observations from national tuberculosis programs and surveys [16] . In addition, market analyses in emerging economies (data for Brazil only have been published to date; data for South Africa, India, and China are to follow) [17] and a literature search of operational research on tuberculosis drug resistance testing were performed. Second, >200 researchers in the field and clinicians, as well as clinical laboratory experts from low-burden and highburden countries, were surveyed about preferences for the prioritization of drug resistance testing, considering currently available and novel regimens (ie, PaMZ and other fluoroquinolone-based regimens), interpretation and use of results with suboptimal performance characteristics, and other related questions (Daniela Cirillo and Martina Casenghi, personal communication, 2014). In addition, mathematical models were used where available to support decision making around optimal test characteristics [18] [19] [20] .
Third, a landscaping exercise was performed to create a knowledge base of available molecular platform technologies and molecular assays that could detect tuberculosis and different resistance targets (FIND, unpublished internal data). This was critical to inform the feasibility of achieving target specification within the expected time frame of development (eg, what can be realistically achieved in terms of performance given a 5-year timeline). Key inputs for this exercise were gathered from literature searches, a survey and discussions with the diagnostics industry and academic groups at trade shows and other venues.
To gain a better understanding of the necessary operational characteristics of the proposed diagnostic test, a survey was conducted of the conditions present in microscopy centers of tuberculosis-endemic countries [21] . Data on the number of microscopy centers and average number of tests performed per center were gathered from publications (Demographic and Health Surveys Project; http://www.measure dhs.com) [22] . Needs associated with throughput, times to results, and results documentation were obtained from clinician and laboratory experts in the field. Expert advice was also obtained to inform specifications around data export and connectivity of the diagnostic test (to enable eHealth and mhealth solutions).
Data to inform the specific price range (ie, the lowest preferred and highest acceptable/affordable cost) for a diagnostic test were difficult to obtain. Ideally, the question of cost should be addressed from several perspectives: What are the costs to the test developers for development and production of a novel test? What is the potential market of a test? What would be a range of pricing that would make the test cost-effective (ie, the cost would be justified by the gain in improved health outcomes and the costs averted with the test, eg, shortened therapy or infection control)? What price of the test would be affordable to high-burden countries, considering their currently available budget for tuberculosis diagnosis? Work is currently ongoing to inform these estimates. A summary of an affordability analysis performed by Pantoja et al is presented as part of this Supplement.
The original draft of the TPP was assembled by FIND with input from all authors. Subsequently, it underwent several rounds of revision, including contributions from the Working Group on Assay Development in the Diagnostic Forum, managed by the Critical Path to Tuberculosis Drug Regimens (CPTR). A shortened version of the TPP was presented to a large stakeholder audience that included >50 clinicians, implementers, and representatives of countries and national tuberculosis programs in a meeting on high-priority target product profiles convened in April 2014 by the WHO on behalf of the Global Laboratory Initiative and the New Diagnostics Working Group of the Stop TB Partnership. The final TPP was published by the WHO and partners in October 2014 [23] . This article discusses the final TPP.
RESULTS
A TPP was compiled using a test developers' perspective with the assumption that new first-line treatment regimens will be implemented and available, at least initially, in parallel to current standard-of-care regimens. We subdivided the TPP by scope, pricing, performance, and operational characteristics (Tables 1-3 ). Each characteristic refers to a specific requirement or specification that is measurable. For each characteristics, a minimal and optimal specification was defined. The minimal specification for a specific characteristic refers to the lowest acceptable specification for that characteristic (although a test may still be acceptable if shortcomings are only missed marginally and are counterbalanced by other advantages). The optimal specification for a specific characteristic provides the ideal value for that characteristic. Meeting the optimal characteristics provides the greatest differentiation from existing methods and the greatest influence for the end users, clinicians and patients. Developers would ideally design and develop their solutions to meet the optimal specification in all characteristics. The optimal and minimal specifications for each characteristic define a range. The characteristics were specified with a development timeline of <5 years in mind.
Scope of Use for the Test
The goal of the assay defined in the TPP is to detect Mycobacterium tuberculosis and antituberculosis drug resistance near the point at which case detection and/or treatment initiation would normally occur (eg, microscopy centers and treatment centers; Table 1 ). Information gained by testing would inform decision making concerning current first-line regimen selection (HRZE, which will likely be available for the foreseeable future), as well as novel regimens (such as PaMZ or other likely fluoroquinolone-based regimens), and/or the need for further testing for resistance to additional drugs. The target population for testing as defined in the TPP is all patients suspected of having tuberculosis, with a special focus on those at high risk of morbidity and mortality from drug-resistant tuberculosis, such as people living with human immunodeficiency virus (HIV), and those at high risk of having MDR tuberculosis (eg, household contacts of patients with MDR tuberculosis, persons with a history of prior tuberculosis, and persons who did not respond to first-line therapy).
Performance Characteristics

M. tuberculosis Detection
As shown in Table 2 , the optimal sensitivity for M. tuberculosis detection is higher than currently achieved by Xpert MTB/RIF (>95%; 95% confidence interval [CI], 90%-100%) when using a single test, compared with 2 liquid cultures (smear negative, >68%; smear positive, >99%) [51] . The optimal sensitivity translates into a limit of detection of <10 2 colony-forming units/assay in 1 sample. The minimal sensitivity of the test should be >80% (95% CI, 70%-90%), with retained high sensitivity in smearpositive patients (smear positive, 99%) and a smear-negative sensitivity of >60%. We set test specificity to allow use in the population of all patients who might be suspected of having tuberculosis. The specificity should be >98% for a single test, compared with the optimal culture technique for the specific drug tested.
No cross-reactivity with other organisms, including nontuberculous mycobacteria, is allowable. Multiplexing capability and the ability to use the platform for different tests (eg, HIV load testing) were judged as valuable features. Although not achievable with existing molecular tests, a test should also be suitable for treatment monitoring, to fully replace smear microscopy.
Resistance Testing
Testing for rifampin, fluoroquinolones (including moxifloxacin), isoniazid, and pyrazinamide resistance was identified as most useful for regimen selection in the near future ( Table 2 ). The TPP prioritized testing for drugs for which resistancecausing mutations have been identified and are known to be of clinically relevant frequency and in which resistance has ≥1of the following 3 consequences: it seriously affects treatment efficacy, increases the risk of resistance amplification, or strongly predicts resistance to other drugs. Fluoroquinolones and pyrazinamide resistance testing were included because, even if the clinical trial results for PaMZ are not satisfactory, it is very likely that these drugs will be part of novel regimens [13] . No specification was made with respect to whether testing for resistance to a drug should be included together with M. tuberculosis detection or whether it should be in a separate step. This decision will depend on many factors, including which performance characteristics can be reached for a certain drug, what the epidemiology of drug resistance is, and what the trade-off might be for including the drugsusceptibility test together with M. tuberculosis detection (eg, in terms of time to diagnosis). Considerations around specific drugs included were as follows. Rifampin is a key component of HRZE and is also an indicator drug for resistance to additional drugs, particularly pyrazinamide and isoniazid (ie, >90% of rifampin-resistant strains are isoniazid resistant and 30%-90% are pyrazinamide resistant) [30] [31] [32] 52] . Fluoroquinolone resistance is less closely associated with rifampin resistance (10%-30% of rifampinresistant strains are fluoroquinolone resistant) [52] . Moxifloxacin is a key component of PaMZ, and it is a suitable replacement of isoniazid in case of isoniazid monoresistance and, along with 
Target population
Target groups are all patients suspected of having tuberculosis, with a special focus on those at high risk of morbidity and mortality from drug-resistant tuberculosis, such as people living with HIV and those at high risk of having MDR tuberculosis (eg, household contacts of patients in whom MDR tuberculosis has been diagnosed and persons with a history of tuberculosis, especially those for whom first-line therapy has failed) in countries with a medium prevalence to a high prevalence of tuberculosis, as defined by the WHO a [1, 24] Target user Healthcare worker with training necessary for performing smear microscopy Lowest setting of implementation (health system level)
Microscopy centers or higher levels of the healthcare system [21, [25] [26] [27] Adapted with permission from [23] .
Abbreviations: HIV, human immunodeficiency virus; HRZE, isoniazid, rifampin, pyrazinamide, ethambutol; MDR, multidrug resistant; PaMZ, Pa824, moxifloxacin, pyrazinamide; WHO, World Health Organization. a High-prevalence countries are those with >40 cases per 100 000 population, medium-prevalence countries are those with 20-40 cases per 100 000 population, and low-prevalence countries are those with <20 cases per 100 000 population [24] .
other fluoroquinolones, is part of the current regimens for MDR tuberculosis [53] . Pyrazinamide is included in HRZE and PaMZ regimens and is a key component for sterilization of infected sites. The prevalence of fluoroquinolone and pyrazinamide resistance (in the absence of rifampin resistance) is poorly defined but is expected to be <3% in most countries across all patients presenting for testing (Matteo Zignol, WHO, personal communication, 2014), with higher values expected in countries where fluoroquinolones are widely used as antibiotic for other infections (eg, India and Pakistan). With this low prevalence, upfront testing of all patients for fluoroquinolone and pyrazinamide resistance would require a highly specific test to avoid high numbers of false-positive results, unless the patients had previously been triaged via the detection of rifampin resistance or unless a false-positive result would have limited adverse impact, owing to the existence of alternative first-line regimens [54] . Isoniazid is a key component of HRZE and the most common source of monoresistance, and it is thus a good candidate for inclusion in resistance testing. However, modeling data (at least for Southeast Asia) show that, on a population level, isoniazid testing has minimal incremental value, compared with testing for rifampin alone, to control MDR and isoniazid resistance [33] . This might change if isoniazid monoresistance increases as more isoniazid preventive therapy is rolled out [34] . Furthermore, the individual benefit of knowing the isoniazid resistance status to guide therapy is indubitable [54] .
Ideally, resistance testing should also inform providers on decisions about second-line therapy. For second-line drugs, resistance testing for aminoglycosides and capreomycin, in addition to fluoroquinolones, would be critical to inform treatment selection for patients with extensively drug-resistant tuberculosis (XDR) or ( pre-) XDR patients (i.e. resistant to either aminoglycosides or fluoroquinolones). However, if inclusion of these drugs results in an increase in test price or complexity, it may be more cost-effective to test for resistance to aminoglycosides and capreomycin with a separate, lower volume test, rather than bundling it with M. tuberculosis detection and resistance testing to first-line drugs.
On the basis of these considerations, the importance of drug resistance testing in near-patient settings was rated as follows, in descending order of importance: rifampin, fluoroquinolones All data should be able to be exported (including data on use of the device, error rates and rates of invalid tests, and personalized, protected results) over a USB port and network; network connectivity should be available through an Ethernet, Wi-Fi, or GSM/ UMTS mobile broadband modem or a combination of these; results should be encoded using a documented standard (such as HL7) and be formatted as JSON text; JSON data should be transmitted through HTTP(S) to a local or remote server as results are generated; results should be stored locally and queued during network interruptions use of the device, error rates or rates of invalid tests, and nonpersonalized results) over a USB port to be sent as a batch when connectivity is restored
Integrated ability for all data to be exported from the device in a userfriendly format (including data on use of the device, error rates or rates of invalid tests, and nonpersonalized results) over a USB port [21, 25, 50] Electronics and software Should be integrated into the instrument Should be integrated into the instrument . . .
Operating temperature/humidity 5°C-50°C at 90% humidity 5°C-40°C at 70% humidity [21, 48] Reagent kit
Transport
No cold chain should be required; should be able to tolerate stress during transport for a minimum of 72 h at −15°C to 50°C
No cold chain required; should be able to tolerate stress during transport for a minimum of 72 h at −15°C to 40°C [21, 25] Storage and stability 2 y at 5°C-40°C with 90% humidity; should be able to tolerate stress during transport for a minimum of 72 h at 50°C ; no cold chain should be required 12 mo at 5°C-35°C with 70% humidity; should be able to tolerate stress during transport for a minimum of 72 h at 50°C; no cold chain should be required [21, 25, 48] Supplies not included in kit None None . . .
Internal quality control
Full controls for sample processing, amplification, and detection of M. tuberculosis should be included [48, 49] Training and education 6 work-hours for staff at the level of a microscopy technician (including moxifloxacin), isoniazid and pyrazinamide (both of which were considered of equal importance), and aminoglycosides/capreomycin. Unless inclusion of resistance testing for a drug adversely affects test cost or performance, all drugs would be included under optimal conditions. The sensitivity of a rapid molecular method to detect drug resistance can be judged in comparison to a genotypic (sequencing) or phenotypic (culture-based) method. Optimally, new tests should detect individual single-nucleotide polymorphisms (SNPs) encoding rifampin, fluoroquinolone, pyrazinamide, isoniazid, and aminoglycoside/capreomycin resistance at least 98% of the time, comparison with sequencing. This threshold should be considered minimally acceptable for rifampin only; for the other drugs, the sensitivity for detection of individual SNPs should be ≥95%. With a phenotypic comparator, resistance to any given drug should be detected with ≥95% sensitivity. Minimally, the same specification is maintained for rifampin resistance but decreases to 90% for detection of fluoroquinolones, pyrazinamide, isoniazid, and aminoglycosides/ capreomycin [1, 28, [37] [38] [39] [40] [41] [42] . Optimal and minimal specificity requirements are identical: ≥98% for any drug resistance testing, compared with either phenotypic resistance testing or the sequencing reference standard [1, 28, [37] [38] [39] 42] .
Operational Characteristics
Because of conditions that prevail in microscopy centers in high-burden countries, tests used in these centers should be robust with very simple sample preparation and minimal operational requirements (Table 3) . The degree to which a test gets adopted will likely depend as much on how well a new product meets the specified operational characteristics as on cost or performance [8, 20] .
Power Requirements/Tolerance to Environmental Conditions Ideally, a test should be battery operated (with a functional life of 24 hours when fully charged) and include a recharging solution (eg, solar) and circuit protector. At a minimum, the platform should be capable of being powered by a standard electrical supply and have a backup with an uninterrupted power supply (UPS) to complete any ongoing testing in case of failure of the AC power supply. The UPS and a circuit protector must be integrated within the system. Tolerance to high temperatures (optimally, up to 50°C) and high humidity (90%) is a key criterion for durability and performance of testing in many tuberculosis-endemic settings (Table 3) .
Maintenance, Calibration, and Integrated Controls Required maintenance should be infrequent (optimally, only every 2 years) with a maintenance alert indicating the need for evaluation. Furthermore, it will be essential that only simple tools and minimal expertise are necessary to do the maintenance, given that service visits are unlikely to be feasible outside of urban settings [48, 49] . No calibration should be required, or remote calibration should be feasible. Full process control, (ie, specifically controlling for sample processing, amplification, and detection) should be integrated into testing [48, 49] .
Time to Result
The need for a rapid turnaround time, the possibility of batching and random access, and the testing of multiple samples at the same time are interrelated in their importance, as all of these will define how many samples can be tested per day and how quickly the patient will receive results [45, 46] . Optimally, the turnaround time should be <30 minutes (for detection and resistance testing); although a minimum of 2 hours for resistance testing alone would be acceptable, ideally, detection of M. tuberculosis would be reported more rapidly, to prevent loss to follow-up [45, 46] .
Sample Preparation
The requirements for the manual sample preparation (ie, the total number of hands-on steps after obtaining the sample) and the results documentation are important characteristics of a test, considering the expertise of the user at the microscopy center level [21, 25] . Optimally, no manual steps or only 1 step should be necessary (and any steps that require precision volume control or precision time steps should be excluded).
Connectivity/Data Export
Although Internet access is not widely available in the settings of intended use, mobile phone capacity is frequently available, even at microscopy centers [21, 25] . This could be leveraged for patient management, quality control, device and supply chain management, and surveillance [50] . Platforms should, ideally, therefore enable full export of data (on device use, error/invalid rates, and personalized, protected results) over a universal serial bus (USB) port and network. The network connectivity should be through Ethernet, Wi-Fi, and/or Global System for Mobile Communications/Universal Mobile Telecommunications System mobile broadband modem. Results should be encoded using a documented standard (such as HL7). At minimum, the platform should have the integrated ability to fully export data (on device sue, error/invalid rates, and nonpersonalized results) from the device in a user-friendly format over a USB port [21, 25] .
Cost
Limited data are available on acceptable cost from the perspectives of developers, national treatment programs, and global funders [55] . A higher price than that of the available technologies (Xpert MTB/RIF and Hain Genotype MTBDRplus are currently available under preferential pricing for approximately $10/test) would be justified only if the new tests bring substantial added value in terms of improved performance, greater suitability for decentralization, and the number of drugs for which resistance can be detected. Cost-effectiveness modeling work is ongoing. A summary of an affordability analysis performed by Pantoja et al is presented as part of this Supplement. Further discussions on an acceptable cost range are necessary as new technologies become available to understand the cost of goods, development, and manufacturing. As the added value in respect to performance and operational characteristics increases, so too might the acceptable costs (to donors like The Global Fund and countries).
DISCUSSION
Expanded availability of drug-susceptibility testing is needed to improve individual patient level outcomes and, as part of tuberculosis control efforts, to improve management of drug resistance. Because of the slowness and complexity of conventional methods, resistance testing is almost never performed at peripheral centers, and results of such tests would therefore not inform selection of first-line therapy when multiple regimens are available [1] . However, testing in the microscopy center requires that a test meet certain operational characteristics to maintain the performance demonstrated in controlled settings [56, 57] . Resistance testing at peripheral settings needs to be complemented by centralized surveillance and testing to inform individualized therapy.
While great strides have been made to improve the understanding of the needs for detection and resistance testing and the various requirements for test use in different healthcare settings, certain key data gaps remain. To improve our understanding of the distribution of drug resistance, the correlation of resistance between drugs, and the trajectories of resistance development over time, population-level surveillance data for different drugs in different regions is necessary. Rifampin and isoniazid data and trajectories are available over recent years, but the understanding of the prevalence of resistance for other drugs is confined to isolated publications [1, 32, 35] . A surveillance effort by the WHO in 5 countries will shed light on the prevalence of pyrazinamide and fluoroquinolone resistance and the correlation with rifampin resistance. This work is complemented by parallel surveillance work in India and China.
Data are also needed on the correlation of mutations with phenotypic results and clinical outcomes and the association with cross-resistance. Here, the scientific community has to work to increase understanding and inform test developers. Efforts to pool sequencing data from different studies and surveillance projects will be essential to better understand the molecular basis of resistance [58] . A coordinated effort to compile the available data across different geographic regions into a database that contains the appropriate meta-data, is vetted and quality controlled, and is readily accessible to all stakeholders is being initiated by FIND, the New Diagnostics Working Group, and the CPTR [59] . Monitoring of resistance for new drugs (eg, bedaquiline and delamanid) and integration into molecular drug-susceptibility testing should also be considered as they become more widely used.
Further implementation research is necessary to better understand barriers to diagnosis and treatment, as well as overtreatment. What is necessary to ensure that test results lead to earlier treatment and minimize loss to follow-up? Data from the phase 3 drug trials and postintroduction surveillance will further guide the understanding of trade-offs of incorrectly identifying sensitivity or resistance (eg, what percentage of patients would acquire resistance to moxifloxacin and Pa-824 if a test failed to identify pyrazinamide resistance and the patient was only treated with 2 effective drugs?).
This ongoing work will aid the refinement of the specifications outlined in the TPP, making it a dynamic tool for communication with investors, partners, and stakeholders and a tool for tracking results toward appropriate assays for testing drug susceptibility in tuberculosis.
Notes
